Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Laser-Ointment combo could replace surgery for skin cancer

NCT ID NCT07010692

Recruiting now Disease control Sponsor: Bruce Robinson, MD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a special laser followed by tirbanibulin ointment can effectively treat common skin cancers like basal and squamous cell carcinoma. About 100 adults with biopsy-confirmed skin cancers will receive the laser treatment and, if needed, apply the ointment for five nights. The goal is to clear the cancer without surgery, improving appearance and recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tirbanibulin ointment 1%
What this could lead to
If successful, this could offer a non-surgical treatment option for common skin cancers, reducing the need for invasive procedures and improving cosmetic outcomes.
What could go wrong
This is an early-phase trial with only 100 participants, so results may not apply to everyone. The treatment may not clear the cancer completely, and recurrence is possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin basal cell carcinoma skin cancer skin neoplasm skin squamous cell carcinoma squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BASAL CELL CARCINOMAS KERATINOCYTE CARCINOMA SKIN CANCER SQUAMOUS CELL CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Bruce Robinson, MD

    RECRUITING

    New York, New York, 10022, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.